Key Product Information Format Lyophilised peptide material Presentation 5 mg laboratory vial Peptide Length 16 amino acids Documentation COA available where applicable What Is AOD-9604
Unlike standard cytoprotective agents that exhibit only prophylactic effectiveness (shared limitation of activity) [41,42,43,44,45,46,47,48], BPC 157 represents a prototype of a more effective class of cytoprotective agents with both prophylactic and therapeutic ability [3,4,5,6,7,8,9,10,11,12,13,14,16,17,18,19,20,21,22,23,24,27,28,29,30,31,32,34,37,39,40]
Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death
To further elucidate the therapeutic mechanisms underlying D-CuPs multivalent interactions, comprehensive proteomic analysis revealed two pivotal transcriptional regulators, the tumor suppressor protein p53 and histone deacetylase 7 (HDAC7) to be potential mechanistic targets
How do I reconstitute BPC-157/TB-500 10MG (Blend)